We are committed to finding a cure for WM.

Medical/Research Updates

FDA Grants Priority Review to Waldenstrom’s Macroglobulinemia Combination Therapy

Source: https://www.raredr.com/news/waldenstroms-macroglobulinemia-combination-therapy-receives-new-drug-designation

Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc announced that the US Food and Drug Administration (FDA) has granted Priority Review for a supplemental New Drug Application (sNDA) for the company’s Waldenström’s macroglobulinemia combination therapy, ibrutinib (IMBRUVICA)… Continue reading

Video: IMBRUVICA (ibrutinib) in Combination With Rituximab for Waldenstrom’s Macroglobulinemia

The following link is to the Cancer Therapy Advisor website featuring the following video

IMBRUVICA (ibrutinib) in Combination With Rituximab for Waldenstrom’s Macroglobulinemia

Meletios Dimopoulos, MD, discusses his findings at the ASCO 2018 meeting in Chicago.

Full link:

https://www.cancertherapyadvisor.com/asco-2018/imbruvica-ibrutinib-combination-rituximab-waldenstrom-macroglobulinemia/article/770910/

Article: Reducing Dose Intensity May Be Associated with Shortened PFS in Waldenstrom Macroglobulinemia

Reducing Dose Intensity May Be Associated with Shortened PFS in Waldenstrom Macroglobulinemia

May 22, 2018

Share this content:

Decreasing the dose intensity (DI) of ibrutinib may reduce progression-free survival (PFS) among patients with Waldenstrom macroglobulinemia (WM)… Continue reading

Article: Ixazomib, Dexamethasone, and Rituximab: Promising for Waldenstrom Macroglobulinemia

Ixazomib, Dexamethasone, and Rituximab: Promising for Waldenstrom Macroglobulinemia

April 26, 2018

Share this content:

Ixazomib, dexamethasone, and rituximab (IDR) may be a safe and effective combination for patients with Waldenstrom macroglobulinemia (WM), according to a… Continue reading

IWMF Global Affiliates

For those around the world, we wanted to share this great poster showing all the global Waldenstrom’s Affiliates.